A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases.
AIBDs
autoimmune bullous diseases
bullous pemphigoid
comorbidities
neuropsychiatric diseases
pemphigus
type 2 diabetes mellitus
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
23
03
2020
revised:
03
04
2020
accepted:
06
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Autoimmune bullous diseases (AIBDs) of the skin and mucosae include a heterogeneous group of chronic diseases, which could be associated with various comorbidities. The purpose of this study was to evaluate the comorbidity profiles of patients affected by AIBDs, who referred to the Dermatological Clinic of Padua from December 2015 to June 2018. A monocentric retrospective observational study was conducted on 157 patients with diagnosis of AIBDs. Patients' comorbidities were investigated during the periodic visits of follow-up and through the analysis of computerized medical records. Among the 157 patients, 40 (25.5%) were diagnosed with PV, 15 (9.6%) with PF, and 102 (64.9%) with BP. Nine different comorbidities were observed, but only two of these were statistically significantly associated with BP: type 2 diabetes (p=0.0142) and neuropsychiatric disorders (p=0.015). BP is statistically significantly associated with type 2 diabetes mellitus and neuropsychiatric diseases. The correlation with neuropsychiatric pathologies is interesting for the possible bidirectional role in their etiology. The association with type 2 diabetes mellitus could suggest more caution in the administration of systemic corticosteroids, especially in elderly patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Autoimmune bullous diseases (AIBDs) of the skin and mucosae include a heterogeneous group of chronic diseases, which could be associated with various comorbidities. The purpose of this study was to evaluate the comorbidity profiles of patients affected by AIBDs, who referred to the Dermatological Clinic of Padua from December 2015 to June 2018.
PATIENTS AND METHODS
METHODS
A monocentric retrospective observational study was conducted on 157 patients with diagnosis of AIBDs. Patients' comorbidities were investigated during the periodic visits of follow-up and through the analysis of computerized medical records.
RESULTS
RESULTS
Among the 157 patients, 40 (25.5%) were diagnosed with PV, 15 (9.6%) with PF, and 102 (64.9%) with BP. Nine different comorbidities were observed, but only two of these were statistically significantly associated with BP: type 2 diabetes (p=0.0142) and neuropsychiatric disorders (p=0.015).
CONCLUSION
CONCLUSIONS
BP is statistically significantly associated with type 2 diabetes mellitus and neuropsychiatric diseases. The correlation with neuropsychiatric pathologies is interesting for the possible bidirectional role in their etiology. The association with type 2 diabetes mellitus could suggest more caution in the administration of systemic corticosteroids, especially in elderly patients.
Identifiants
pubmed: 32606191
pii: 34/4/2113
doi: 10.21873/invivo.12016
pmc: PMC7439873
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2113-2118Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Mult Scler. 2010 Jul;16(7):855-61
pubmed: 20463037
Clin Dev Immunol. 2013;2013:240570
pubmed: 23878581
Int J Dermatol. 2017 Oct;56(10):1010-1016
pubmed: 28856675
Br J Dermatol. 2016 Aug;175(2):296-301
pubmed: 27031194
Thromb J. 2015 Apr 23;13:16
pubmed: 25908929
Arch Dermatol. 2010 Nov;146(11):1251-4
pubmed: 21079062
World J Gastroenterol. 2013 Apr 21;19(15):2298-306
pubmed: 23613622
J Am Acad Dermatol. 2014 Dec;71(6):1191-7
pubmed: 25174542
Lancet. 2012 Jan 21;379(9812):244-9
pubmed: 22119579
J Diabetes Investig. 2019 Sep;10(5):1168-1170
pubmed: 30989811
Adv Clin Exp Med. 2019 May;28(5):637-642
pubmed: 30784240
Biol Chem. 2016 Apr;397(4):283-96
pubmed: 26859499
J Diabetes Investig. 2019 Mar;10(2):392-398
pubmed: 29920976
Curr Opin Hematol. 2013 Sep;20(5):457-63
pubmed: 23892572
BMC Med. 2011 Jan 10;9:1
pubmed: 21219637
Clin Rheumatol. 2014 Mar;33(3):297-304
pubmed: 24424839
QJM. 2014 Oct;107(10):793-7
pubmed: 24713224
Skin Therapy Lett. 2014 Sep-Oct;19(5):1-6
pubmed: 25405675
N Engl J Med. 2002 Jan 31;346(5):321-7
pubmed: 11821508
Acta Derm Venereol. 2019 May 1;99(6):602-609
pubmed: 30848289
Gerontology. 2011;57(3):211-6
pubmed: 20664178
Eur J Dermatol. 2010 Jan-Feb;20(1):96-101
pubmed: 19797038
J Dermatol Sci. 1995 Mar;9(2):136-41
pubmed: 7772576
Ann Rheum Dis. 2016 Jan;75(1):148-54
pubmed: 25265937
Aging Clin Exp Res. 2016 Aug;28(4):659-63
pubmed: 26420424
J Dermatol. 2016 Feb;43(2):125-33
pubmed: 26435381
An Bras Dermatol. 2014 Mar-Apr;89(2):274-8
pubmed: 24770504
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1758-62
pubmed: 25651418
Acta Derm Venereol. 2015 Mar;95(3):307-11
pubmed: 24979241
Dermatol Online J. 2017 Dec 15;23(12):
pubmed: 29447647
PLoS One. 2015 Jun 09;10(6):e0129456
pubmed: 26057532
Front Immunol. 2018 Apr 12;9:542
pubmed: 29706950
JAMA Dermatol. 2013 Jan;149(1):58-62
pubmed: 23324757
Indian J Dermatol Venereol Leprol. 2018 Jan-Feb;84(1):22-26
pubmed: 29185440
Br J Dermatol. 1990 Oct;123(4):439-45
pubmed: 2095174
Clin Exp Dermatol. 2007 May;32(3):291-4
pubmed: 17397352
J Diabetes Investig. 2012 Dec 20;3(6):503-9
pubmed: 24843615
Psychopharmacology (Berl). 2016 May;233(9):1623-36
pubmed: 26803500
Br J Dermatol. 2011 Sep;165(3):593-9
pubmed: 21517800
Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):195-199
pubmed: 27679408
Hamostaseologie. 2010 Jan;30(1):5-6, 8-9
pubmed: 20162248
Int J Dermatol. 1991 May;30(5):307-12
pubmed: 1829722
Clin Exp Dermatol. 2015 Aug;40(6):593-9
pubmed: 25786337
Trends Cardiovasc Med. 2005 Oct;15(7):254-9
pubmed: 16226680